239 related articles for article (PubMed ID: 26026369)
1. Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model.
Trifilieff A; Ethell BT; Sykes DA; Watson KJ; Collingwood S; Charlton SJ; Kent TC
Toxicol Appl Pharmacol; 2015 Aug; 287(1):9-16. PubMed ID: 26026369
[TBL] [Abstract][Full Text] [Related]
2. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.
Gavaldà A; Ramos I; Carcasona C; Calama E; Otal R; Montero JL; Sentellas S; Aparici M; Vilella D; Alberti J; Beleta J; Miralpeix M
Pulm Pharmacol Ther; 2014 Aug; 28(2):114-21. PubMed ID: 24928173
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.
Pulido-Rios MT; McNamara A; Obedencio GP; Ji Y; Jaw-Tsai S; Martin WJ; Hegde SS
J Pharmacol Exp Ther; 2013 Aug; 346(2):241-50. PubMed ID: 23685545
[TBL] [Abstract][Full Text] [Related]
4. The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium.
Sykes DA; Dowling MR; Leighton-Davies J; Kent TC; Fawcett L; Renard E; Trifilieff A; Charlton SJ
J Pharmacol Exp Ther; 2012 Nov; 343(2):520-8. PubMed ID: 22854200
[TBL] [Abstract][Full Text] [Related]
5. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Prakash A; Babu KS; Morjaria JB
Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
[TBL] [Abstract][Full Text] [Related]
7. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.
Buhl R; Banerji D
Int J Chron Obstruct Pulmon Dis; 2012; 7():729-41. PubMed ID: 23118536
[TBL] [Abstract][Full Text] [Related]
8. Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics.
Blais CM; Davis BE; Cockcroft DW
Respir Med; 2016 Sep; 118():96-101. PubMed ID: 27578477
[TBL] [Abstract][Full Text] [Related]
9. Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist.
Villetti G; Pastore F; Bergamaschi M; Bassani F; Bolzoni PT; Battipaglia L; Amari G; Rizzi A; Delcanale M; Volta R; Cenacchi V; Cacciani F; Zaniboni M; Berti F; Rossoni G; Harrison S; Petrillo P; Santoro E; Scudellaro R; Mannini F; Geppetti PA; Razzetti R; Patacchini R; Civelli M
J Pharmacol Exp Ther; 2010 Dec; 335(3):622-35. PubMed ID: 20805306
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs.
Casarosa P; Bouyssou T; Germeyer S; Schnapp A; Gantner F; Pieper M
J Pharmacol Exp Ther; 2009 Aug; 330(2):660-8. PubMed ID: 19478135
[TBL] [Abstract][Full Text] [Related]
11. Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.
Tashkin DP; Gross NJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():1873-1888. PubMed ID: 29928118
[TBL] [Abstract][Full Text] [Related]
12. Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.
Molimard M; D'Andrea P
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):503-17. PubMed ID: 23971870
[TBL] [Abstract][Full Text] [Related]
13. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
Riario-Sforza GG; Ridolo E; Riario-Sforza E; Incorvaia C
Expert Rev Respir Med; 2015 Feb; 9(1):23-33. PubMed ID: 25547422
[TBL] [Abstract][Full Text] [Related]
14. [Tiotropium (Spiriva) - a long-acting inhaled anticholinergic for the treatment of chronic obstructive pulmonary disease (COPD)].
Beeh KM; Welte T; Buhl R
Pneumologie; 2003 Sep; 57(9):519-25. PubMed ID: 13680472
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways.
Villetti G; Bergamaschi M; Bassani F; Bolzoni PT; Harrison S; Gigli PM; Janni A; Geppetti P; Civelli M; Patacchini R
Br J Pharmacol; 2006 Jun; 148(3):291-8. PubMed ID: 16565730
[TBL] [Abstract][Full Text] [Related]
16. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.
Vogelmeier C; Banerji D
Ther Adv Respir Dis; 2011 Jun; 5(3):163-73. PubMed ID: 21511677
[TBL] [Abstract][Full Text] [Related]
17. Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study.
Drollmann A; Sechaud R; Pal P; Hara H; Uziel-Fusi S; Winkle P
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):739-45. PubMed ID: 24986094
[TBL] [Abstract][Full Text] [Related]
18. Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.
D'Urzo AD; Kerwin EM; Chapman KR; Decramer M; DiGiovanni R; D'Andrea P; Hu H; Goyal P; Altman P
Int J Chron Obstruct Pulmon Dis; 2015; 10():1599-612. PubMed ID: 26316734
[TBL] [Abstract][Full Text] [Related]
19. Comparative characterization of lung muscarinic receptor binding after intratracheal administration of tiotropium, ipratropium, and glycopyrrolate.
Ogoda M; Niiya R; Koshika T; Yamada S
J Pharmacol Sci; 2011; 115(3):374-82. PubMed ID: 21358117
[TBL] [Abstract][Full Text] [Related]
20. Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).
Ulrik CS
Expert Opin Pharmacother; 2015; 16(17):2653-9. PubMed ID: 26641535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
